Nanordica Medical Raises €1.6 Mn in Round led by 2C Ventures

The funding round was led by 2C Ventures and also included investments from existing backers such as Specialist VC, Superangel, Amalfi, the Health Founders syndicate led by Erki Mölder, and the EstBAN syndicate led by Heidi Kakko and Martin Goroško.

Around 100 million people worldwide suffer from chronic wounds that do not heal properly. More than half of these wounds become infected which can lead to serious health problems such as sepsis, amputations, and even death.

Among chronic wounds, diabetic foot ulcers are one of the most common and serious types. They are a leading cause of infections and leg amputations in people with diabetes.

Based on earlier research results, Nanordica Medical is now running a large clinical study across multiple medical centers. The study is double-blind and randomized and includes more than 120 patients, making it one of the largest studies of its kind.

The company hopes the trial will provide the medical evidence needed for insurance and healthcare reimbursement decisions, future treatment guidelines, and wider use of its wound-healing technology.

“Antimicrobial resistance is one of the defining healthcare challenges of this decade, and most wound care products are making it worse,” said Martin Koppel, Founding Partner at 2C Ventures. “Nanordica has built a clinically proven alternative that doesn't rely on antibiotics, doesn't compromise healing, and leaves a significantly smaller environmental footprint. We backed the team because they had both the science and the conviction to see this through.”

Before launching its product commercially, Nanordica Medical has already reached several important milestones. These include receiving ISO 13485 certification for its quality management system, securing a European patent, and successfully launching Ravimus Vet, a wound-care product for animals that is now sold in six countries.

The company has also gained industry recognition. Market research firm SmartTRAK recently named Nanordica as one of the four advanced wound-care companies to watch in the global wound care market.

“This financing round will enable us to complete a large randomised clinical study, strengthen the economic case for Premotiv®, and finalise CE marking for commercial launch in Europe,” said Olesja Bondarenko, CEO and co-founder of Nanordica Medical. “Our clinical data suggest that Premotiv® helps wounds heal faster by managing infection without compromising natural healing processes. Faster healing has the potential to reduce complications, lower treatment costs, and improve outcomes for patients with chronic wounds.”

The new funding will help Nanordica Medical complete its ongoing clinical trial, finish the regulatory steps needed to obtain CE marking, and launch its human wound-care product across Europe.

These efforts build on earlier support from a €2.4 million grant from the European Innovation Council (EIC) Accelerator, which helped the company fund clinical research, prepare for regulatory approval, and expand its product development.

Read Also- NEURA Robotics Raises Up to $1.4 Billion to Expand AI-Powered Robotics Platform